Genprex Future Growth

Future criteria checks 0/6

Genprex's earnings are forecast to decline at 8.3% per annum while its annual revenue is expected to grow at 85.7% per year. EPS is expected to grow by 95.3% per annum.

Key information

-8.3%

Earnings growth rate

95.3%

EPS growth rate

Biotechs earnings growth	21.3%
Revenue growth rate	85.7%
Future return on equity	n/a
Analyst coverage	Low
Last updated	10 Apr 2024

Recent future growth updates

Recent updates

Genprex stock rises 13% on safety panel nod to continue trial of Reqorsa/Tagrisso combo for lung cancer

Aug 15

We're Not Very Worried About Genprex's (NASDAQ:GNPX) Cash Burn Rate

Jun 14

Here's Why We're Not Too Worried About Genprex's (NASDAQ:GNPX) Cash Burn Situation

Feb 09

Genprex: Limited Clinical Data To Justify Risk

Nov 19

We Think Genprex (NASDAQ:GNPX) Can Afford To Drive Business Growth

Oct 27

Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Jun 11

Genprex receives IRB approval for NSCLC gene therapy trial; shares up 4%

May 05

Genprex' stock jumps after corporate update

Feb 01

Genprex achieves manufacturing milestone for immunogene therapy for upcoming lung cancer trials

Jan 13

Genprex completes manufacturing scale-up of lung cancer therapy

Dec 22

Earnings and Revenue Growth Forecasts

NasdaqCM:GNPX - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	N/A	-40	N/A	N/A	1
12/31/2025	N/A	-32	N/A	N/A	1
12/31/2024	N/A	-24	N/A	-26	1
12/31/2023	N/A	-31	-25	-25	N/A
9/30/2023	N/A	-31	-24	-24	N/A
6/30/2023	N/A	-30	-24	-24	N/A
3/31/2023	N/A	-28	-21	-21	N/A
12/31/2022	N/A	-24	-18	-18	N/A
9/30/2022	N/A	-24	-17	-16	N/A
6/30/2022	N/A	-21	-14	-14	N/A
3/31/2022	N/A	-19	-13	-13	N/A
12/31/2021	N/A	-21	-14	-14	N/A
9/30/2021	N/A	-19	-17	-15	N/A
6/30/2021	N/A	-18	-17	-14	N/A
3/31/2021	N/A	-19	-17	-15	N/A
12/31/2020	N/A	-18	-16	-14	N/A
9/30/2020	N/A	-15	-12	-12	N/A
6/30/2020	N/A	-15	-12	-12	N/A
3/31/2020	N/A	-14	-11	-10	N/A
12/31/2019	N/A	-11	-8	-7	N/A
9/30/2019	N/A	-12	-8	-7	N/A
6/30/2019	N/A	-11	-8	-7	N/A
3/31/2019	N/A	-14	-8	-8	N/A
12/31/2018	N/A	-12	-7	-7	N/A
9/30/2018	N/A	-10	-5	-5	N/A
6/30/2018	N/A	-8	-4	-4	N/A
3/31/2018	N/A	-3	-2	-2	N/A
12/31/2017	N/A	-3	-2	-2	N/A
9/30/2017	N/A	-4	N/A	-3	N/A
6/30/2017	N/A	-4	N/A	-2	N/A
3/31/2017	N/A	-5	N/A	-2	N/A
12/31/2016	N/A	-4	N/A	-1	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GNPX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GNPX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GNPX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: GNPX is forecast to have no revenue next year.

High Growth Revenue: GNPX is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if GNPX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Genprex Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

No longer forecast to breakeven

Price target increased to US$6.23

Price target increased to US$6.50

Price target increased to US$8.25

Forecast to breakeven in 2024

Recent updates

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer

Genprex, Inc. has completed a Follow-on Equity Offering.

Genprex, Inc. has filed a Follow-on Equity Offering.

Genprex, Inc. has filed a Follow-on Equity Offering.

Genprex, Inc. Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers

Insufficient new directors

Genprex, Inc. Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators

Genprex, Inc. Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer

New major risk - Market cap size

Genprex, Inc. to Present Data on the Use of Reqorsa for the Treatment of Lung Cancers At 2023 Aacr-Nci-Eortc International Conference on Molecular Targets and Cancer Therapeutics

Genprex Receives Non-Compliance Notice From Nasdaq

Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs

Genprex, Inc. announced delayed 10-Q filing

Can Genprex (NASDAQ:GNPX) Afford To Invest In Growth?

Genprex, Inc. Receives Fast Track Designation from the FDA for Its Small Cell Lung Cancer Drug Candidate

Genprex, Inc. Grants Chinese Patent for REQORSA(R) Immunogene Therapy in Combination with PD-1 Antibodies to Treat Cancers

Genprex Receives U.S. FDA Fast Track Designation for REQORSA Immunogene Therapy in Combination with Tecentriq for the Treatment of Small Cell Lung Cancer

Genprex, Inc. Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA(R) in Combination with Tagrisso(R) in Advanced Non-Small Cell Lung Cancer

Genprex, Inc. Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating Reqorsa Immunogene Therapy in Non-Small Cell Lung Cancer

Genprex, Inc. announced delayed 10-Q filing

No longer forecast to breakeven

Here's Why We're Watching Genprex's (NASDAQ:GNPX) Cash Burn Situation

Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA(R) in Combination with Tagrisso(R) in Advanced Non-Small Cell Lung Cancer

Price target increased to US$6.23

High number of new and inexperienced directors

Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA™ in Combination with Tagrisso® in Non-Small Cell Lung Cancer

Genprex stock rises 13% on safety panel nod to continue trial of Reqorsa/Tagrisso combo for lung cancer

We're Not Very Worried About Genprex's (NASDAQ:GNPX) Cash Burn Rate

Price target increased to US$6.50

High number of new and inexperienced directors

Genprex, Inc. Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancercer

Genprex, Inc. Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA Immunogene Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer

Genprex, Inc. Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA Immunogene Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer

Here's Why We're Not Too Worried About Genprex's (NASDAQ:GNPX) Cash Burn Situation

Genprex, Inc. Announces Positive Preclinical Data for Use of Genprex’s ONCOPREX® Nanoparticle Delivery System for Delivery of FAS DNA Plasmid to Treat Metastatic Colorectal Cancer

Genprex, Inc. to Accelerate Opening of Acclaim-1 Clinical Trial Sites

Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer

Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer

Genprex: Limited Clinical Data To Justify Risk

We Think Genprex (NASDAQ:GNPX) Can Afford To Drive Business Growth

Genprex, Inc.(NasdaqCM:GNPX) dropped from Russell 3000E Index

Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review

Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Price target increased to US$8.25

Forecast to breakeven in 2024

Genprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer

Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

Genprex receives IRB approval for NSCLC gene therapy trial; shares up 4%

Genprex, Inc. Announces Formation of Clinical Advisory Board

Genprex' stock jumps after corporate update

Genprex, Inc. Achieves Major Manufacturing Milestone for REQORSA™ Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer

Genprex achieves manufacturing milestone for immunogene therapy for upcoming lung cancer trials

Genprex, Inc. Completes Manufacturing Scale-Up for Clinical-Grade Production of REQORSA™ Immunogene Therapy for Upcoming Acclaim-1 and Acclaim-2 Clinical Trials For Lung Cancer

Genprex completes manufacturing scale-up of lung cancer therapy

Genprex, Inc Completes Manufacturing Technology Transfer for Novel Gene Therapy

Genprex Initiates Site Recruitment for Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

Genprex, Inc. Appoints George K. Gittes to Its Scientific Advisory Board

Genprex, Inc. Promotes Eric Chapdelaine to Vice President of Manufacturing

Genprex, Inc. Names Thomas C. Gallagher, Esq. as Senior Vice President of Intellectual Property and Licensing

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies